Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

Rhea-AI Summary

Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 on April 20, 2022, at 3:55 p.m. ET. His presentation is titled “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.” Dr. Tucker will share data highlighting the potential benefits of Vaxart’s oral tablet COVID-19 vaccine candidate, which is currently in clinical development.

Vaxart develops oral recombinant vaccines that can be stored without refrigeration, aiming to create vaccines for various diseases, including coronavirus and HPV.

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.

 The title of Dr. Tucker’s presentation is “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.” Dr. Tucker will discuss data supporting the potential benefits of Vaxart’s oral tablet COVID-19 vaccine candidate, which is in clinical development.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts   

Vaxart Media Relations:	Investor Relations:
Mark Herr	Andrew Blazier
Vaxart, Inc.	FINN Partners
mherr@vaxart.com	IR@Vaxart.com
(203) 517-8957	(646) 871-8486

FAQ

What is Vaxart presenting at the World Vaccine Congress 2022?

Vaxart will present on April 20, 2022, discussing the potential benefits of its oral tablet COVID-19 vaccine candidate.

Who is presenting for Vaxart at the World Vaccine Congress?

Dr. Sean Tucker, SVP and Chief Scientific Officer, will present for Vaxart.

What is the title of Dr. Tucker's presentation at the World Vaccine Congress?

The title is “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.”

What is Vaxart's COVID-19 vaccine candidate?

Vaxart's COVID-19 vaccine candidate is an oral tablet vaccine currently in clinical development.

When will Vaxart's presentation take place?

The presentation will take place on April 20, 2022, at 3:55 p.m. ET.